Develop a next-generation, mucosally delivered, covid-19 booster vaccine capable of eliciting mucosal immunity and protecting against sars-COV-2 breakthrough infection and transmission

Ended Definitive Contract Awarded Last action

Contract number
75A50123C00065
Awardee
Awarding agency
Obligated
$8,294,985

Award facts

Opportunity
Contract value 2% obligated
  • $8,294,985.00 Current, with exercised options
  • $338,869,093.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
New York, NY 10014, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00007 · The purpose of this modification is to update the period of performance end date from august 2, 2027, to january 31, 2025. $0
Other Administrative Action P00006 · The purpose of this modification is to update section J, attachment #1 ? Statement of work to remove WBS 1.2.10.6, 1.2.10.7 and update attachment #9, part I… -$103,934
Other Administrative Action P00005 · The purpose of this modification is to extend the base period of performance through january 31, 2025, at no additional cost to the government, update… $0
Other Administrative Action P00004 · No cost modification to update section G.3 key personnel. $0
Other Administrative Action P00003 · No cost modification to extend the base period of performance. $0
Other Administrative Action P00002 · No cost modification to contracting officer (CO) and update section G.4 contract financial report. $0
Other Administrative Action P00001 · Administrative modification $0
Original award $8,398,919

About this award

Written by GovTribe AI ·

The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $338.9 million firm fixed-price contract to Castlevax Inc. on September 30, 2023, to develop a next-generation, mucosally delivered COVID-19 booster vaccine capable of eliciting mucosal immunity and protecting against SARS-CoV-2 breakthrough infection and transmission. The contract is being performed in New York, New York, with an ultimate completion date of January 31, 2025. This award originated from a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA) seeking advanced research and development of medical countermeasures against pandemic threats, including vaccines and therapeutics advancing toward FDA approval or licensure. The contract was not issued under any set-aside designation.

This procurement represents ASPR's continued investment in pandemic preparedness and vaccine development capabilities through BARDA's established programs. A recent modification to the contract adjusted the period of performance end date from August 2, 2027, to January 31, 2025, reflecting a change in project timeline. Castlevax's mucosal vaccine approach represents an advancement beyond traditional intramuscular administration, targeting enhanced respiratory tract immunity to reduce both breakthrough infections and viral transmission in the context of ongoing COVID-19 variant evolution.

Quick answers

Who was awarded contract 75A50123C00065?

75A50123C00065 was awarded to Castlevax Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 30, 2023.

How much is contract 75A50123C00065 worth?

The government has obligated $8,294,985 on 75A50123C00065. Its potential value, with all options, is $338,869,093.

Was contract 75A50123C00065 competed?

The extent of competition for 75A50123C00065 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login